ROCKWELL MEDICAL, INC.

Rockwell Medical, Inc. announced a transformational acquisition of Vantive Limited's global hemodialysis business for a base purchase price of $125 million. The deal, expected to close mid-2027, includes Vantive's concentrates, machines, water treatment systems, and related services, establishing Rockwell Medical as a major global player in the hemodialysis market. The combined entity is projected to generate annual revenues between $400 million and $450 million. The acquisition will be financed through seller financing, including term loans and a convertible note, with potential for additional contingent payments. Rockwell Medical has withdrawn its 2026 financial guidance due to anticipated transaction-related expenses.

Rockwell Medical, Inc. reported a 10.6% increase in net sales for the second quarter of 2026, reaching $17.78 million, while its net loss improved to $(1.17) million from $(1.49) million in the prior year. For the six months ended June 30, 2026, the company generated $1.91 million in net cash from operating activities, a significant improvement from a net cash usage of $(1.64) million in the same period last year. The company also completed a 1-for-10 reverse stock split on July 1, 2026, and maintains $24.8 million in cash, cash equivalents, and investments.

Rockwell Medical announced its second quarter 2026 financial results, reporting an 11% year-over-year increase in net sales to $17.8 million and a 30% rise in gross profit to $3.2 million. The company's net loss improved to $1.2 million, and it generated $2.1 million in cash flow from operations, boosting its cash position to $24.8 million. Rockwell Medical also reiterated its full-year 2026 guidance and highlighted new and renewed product purchase agreements, alongside regaining Nasdaq compliance after a reverse stock split.

Rockwell Medical, Inc. announced it has regained compliance with The Nasdaq Stock Market LLC's minimum $1.00 per share bid price requirement for continued listing. The company maintained a closing bid price of $1.00 or greater for 10 consecutive business days, from July 1 to July 15, 2026. As a result, Nasdaq has closed the compliance matter, and Rockwell Medical is now in full compliance with all Nasdaq listing requirements.

Rockwell Medical, Inc. has filed an amendment to its certificate of incorporation to effect a one-for-ten reverse stock split of its common stock. The split, approved by stockholders, will become effective at 12:01 a.m. Eastern Time on July 1, 2026, with trading on a split-adjusted basis commencing the same day under a new CUSIP number. Fractional shares will be paid in cash, and proportionate adjustments will be made to outstanding equity awards, preferred stock, and warrants.

Rockwell Medical, Inc. received a notice from Nasdaq on May 8, 2026, indicating non-compliance with the minimum bid price requirement of $1.00 per share. The company's common stock traded below $1.00 for 30 consecutive business days. Rockwell Medical has 180 calendar days, until November 4, 2026, to regain compliance. The company plans to propose a reverse stock split to its stockholders to address this issue.

Rockwell Medical, Inc. announced on May 7, 2026, that it has made available an updated corporate presentation. This presentation is furnished as Exhibit 99.1 to the Form 8-K filing, providing stakeholders with the latest company information.

Rockwell Medical reported a decrease in net sales and an increase in net loss for the first quarter of 2026 compared to the same period in 2025. Net sales fell by 8.3% to $17.3 million, while net loss grew to $1.6 million. Despite these financial declines, the company improved its net cash used in operating activities and maintains $23.9 million in cash, cash equivalents, and available-for-sale investments, with management believing it has sufficient funds for the next twelve months. However, a significant customer, DaVita, plans to transition to another supplier, although their agreement has been extended through December 2026.

Rockwell Medical announced its first quarter 2026 financial results, reporting $17.3 million in net sales, an 8% decrease year-over-year, and a net loss of $1.6 million. Despite the sales decline, gross margin slightly improved to 17%. The company also provided updated 2026 guidance, emphasizing growth, improved gross margin, and generating positive cash flow, driven by operational changes expected to yield over $3 million in additional annualized gross profit and over $2 million in annualized savings.

Rockwell Medical, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 12, 2026. Key proposals include the election of two Class II directors, an advisory vote on executive compensation, and the ratification of EisnerAmper LLP as the independent auditor. The company also seeks approval for an amendment to its Certificate of Incorporation to effect a reverse stock split of its common stock.